Biological Dynamics to Present at the 2022 UBS Genomics 2.0 and MedTech Innovations Summit

Wednesday, August 10, 2022 at 1:00 p.m. ET / 10:00 a.m. PT

SAN DIEGO--(BUSINESS WIRE)--Biological Dynamics, Inc., a biotechnology company focused on detecting diseases at their earliest stages, today announced that the company will participate at the 2022 UBS Genomics 2.0 and MedTech Innovations Summit in Dana Point, California.

Dr. Paul Billings, CEO and Kevin Han, CFO are scheduled to participate in a fireside chat with UBS analysts on Wednesday, August 10th at 1:00 p.m. ET / 10:00 a.m. PT.

The company will discuss commercial launch plans for its first assay, an early-stage pancreatic cancer detection test, using enriched exosomal protein biomarkers on the company’s proprietary Verita™ isolation platform. Last month, in July 2022, this platform received the Audience Choice Award for the Disruptive Technology Competition at the 2022 American Association for Clinical Chemistry (AACC) Annual Scientific Meeting & Clinical Lab Expo in Chicago, IL.

To join the live webcast, visit Biological Dynamics’ website: https://biologicaldynamics.com/company-events. Following the presentation, the webcast recording will be available for replay.

About Biological Dynamics

Biological Dynamics, Inc. is a biotechnology company committed to improving global health outcomes by detecting diseases at their earliest stages. Our proprietary Verita™ platform simplifies access to biomarkers, nanoparticles, and nucleic acids, enabling differentiated multiomic applications. We are applying our proprietary methods with machine learning to detect several diseases, including cancer, in blood and other bodily fluids, at our CAP/CLIA accredited clinical laboratory in San Diego. For more information, please visit www.biologicaldynamics.com and follow us at @BiodynSD on Twitter.

Kevin Han
Chief Financial Officer
kevin.han@biodyn.io